Evidence map›Paper›PMID 30245818›Full record

ArticleSAGE open medicine2018

A novel prostate cancer immunotherapy using prostate-specific antigen peptides and

Al-Ola Abdallah, Hannah Coleman, Mohamed Kamel, Rodney Davis, Teri Landrum, Horace Spencer, Sam Mackintosh, Fade A Mahmoud, Natasa Milojkovic, Chester Wicker and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Al-Ola AbdallahDepartment of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Hannah ColemanDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Mohamed KamelDepartment of Urology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Rodney DavisDepartment of Urology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Teri LandrumDivision of Hematology and Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Horace SpencerDepartment of Biostatistics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Sam MackintoshDepartment of Biochemistry and Molecular Biology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Fade A MahmoudDepartment of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Natasa MilojkovicDepartment of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Chester WickerDivision of Hematology and Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Konstantinos ArnaoutakisDepartment of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Mayumi NakagawaDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID https://orcid.org/0000-0002-0377-4613
University of Arkansas for Medical Sciences · USWinthrop Rockefeller Foundation · USAin Shams University · EGUniversity Medical Center · US

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett, JERRY WARE · 2012 to 2026
$60.9M
Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2012 to 2021
$21.5M
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-RenewalR01CA143130 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAKAGAWA, MAYUMI · 2010 to 2025
$10.0M
Center for Protein Structure and FunctionP30GM103450 · NIGMS · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI MILLETT, FRANCIS S · 2012 to 2014
$3.2M
Orbitrap Fusion Tribrid Mass SpectrometerS10OD018445 · OD · UNIV OF ARKANSAS FOR MED SCIS · PI MACKINTOSH, SAMUEL G. · 2015 to 2015
$856k
NCI NIH HHS R01 CA143130NIGMS NIH HHS P20 GM103429NIGMS NIH HHS P20 GM103625NIGMS NIH HHS P30 GM103450NIH HHS S10 OD018445
6 · The paper itself

Abstract

objectivesOur group developed the use of the

methodsPeptides based on the prostate-specific antigen amino acid sequences were selected, synthesized, and evaluated in terms of their (1) solubility, (2) maturation effects on Langerhans cells by fluorescence-activated cell sorter analysis, and (3) recognition by peripheral immune cells from prostate cancer patients using interferon-γ enzyme-linked immunospot assay.

resultsThe peptides were soluble in 10 mM succinate at pH of 5 with 5% glycine, and they demonstrated no maturation effects on Langerhans cells from healthy donors. On the other hand, peripheral immune cells from 4 of 10 prostate cancer patients examined had positive responses in enzyme-linked immunospot assay to one or more prostate-specific antigen peptides.

conclusionIn summary, a design and a formulation of a novel prostate cancer immunotherapy are described. The immunogenicity of prostate-specific antigen peptides in some prostate cancer patients supports further development of this immunotherapy.

Indexed as

CandidaLangerhans cellspeptidesprostate cancerProstate-specific antigen

Identifiers

PMID30245818
PMCPMC6144584
OpenAlexW2889795039

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.